Name | quetiapine fumarate |
Synonyms | quetiapine fumarate QUETIAPINE HEMIFUMERATE Quetiapine fuMarate USP Quetiapine hemifumarate Quetiapine Fumarate Tablets Quetiapine heMifuMarate salt Quetiapine (hemifumarate) (CRM) quetiapine fumarate main intermediates 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol hemifumarate 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol (2E)-but-2-enedioate (salt) |
CAS | 111974-72-2 |
EINECS | 1308068-626-2 |
InChI | InChI=1S/2C21H25N3O2S.C4H4O4/c2*25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21;5-3(6)1-2-4(7)8/h2*1-8,25H,9-16H2;1-2H,(H,5,6)(H,7,8)/b;;2-1+ |
Molecular Formula | C46H54N6O8S2 |
Molar Mass | 883.09 |
Melting Point | 174-176°C |
Boling Point | 556.5°C at 760 mmHg |
Flash Point | 9℃ |
Solubility | DMSO 36 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
Vapor Presure | 3.22E-13mmHg at 25°C |
Appearance | White to white-like powder |
Color | white to off-white |
Merck | 14,8039 |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Sensitive | Sensitive to heat |
MDL | MFCD03423782 |
Physical and Chemical Properties | White crystalline powder. |
In vitro study | Quetiapine has affinity for various neurotransmitter receptors, including serotonin, dopamine, histamine, and adrenergic receptors, and has similar affinity for dopamine -2 receptors and clozapine. |
In vivo study | Quetiapine has antipsychotic activity, reduces the tendency to cause extrapyramidal symptoms (EPS) and persistent prolactin elevations. Guetiapine alters brain limbic neurotensin neurotransmitter and c-fos expression, but not motor areas of the brain. Guetiapine is realized similar to clozapine in behavioral and biochemical test activity, and may have neuroprotective properties. Quetiapine dose-dependently prevents chronic restraint stress (CRS)-induced hippocampal cell proliferation and BDNF expression in schizophrenia and depression. The combination of Guetiapine(5 mg/kg) and Venlafaxine( 2.5 mg/kg) increased hippocampal cell proliferation and prevented BDNF reduction in stressed rats, while alone had little or no effect. Guetiapine produces a selective effect on dopaminergic neurotransmission in the cerebral cortex and limbic zones, especially in these regions. Guetiapine produces putamenal DA D2R to occupy lower levels than those reported for typical APD. Guetiapine also produced an occupancy ratio of d2r46.9% for temporal cortex dopamine. In rats with chronic restraint stress, Guetiapine reduces the level of brain-derived neurotrophic factor (BDNF) in the hippocampus. Guetiapine(10 mg/kg) reversed the stress-induced inhibition of hippocampal neurogenesis, as reflected in the numbers of BrdU-positive and pCREB-positive cells, which were close to but higher than those of non-stressed rats. |
Risk Codes | R22 - Harmful if swallowed R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R39/23/24/25 - R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R11 - Highly Flammable |
Safety Description | S60 - This material and its container must be disposed of as hazardous waste. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37 - Wear suitable protective clothing and gloves. S16 - Keep away from sources of ignition. |
UN IDs | UN1230 - class 3 - PG 2 - Methanol, solution |
WGK Germany | 3 |
RTECS | KK3605000 |
HS Code | 29349990 |